- |||||||||| Jorveza (budesonide orodispersible tablets) / Dr Falk
Review, Journal: Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence? (Pubmed Central) - Nov 3, 2023 Budesonide orodispersible tablet (BOT) and budesonide oral suspension (BOS) both surpassed placebo formulations regarding the efficacy of inducing and maintaining histologic, symptomatic and endoscopic remission...Fluticasone propionate (APT-1011) achieved and maintained histologic and endoscopic responses in the majority of patients, whereas only a positive trend was demonstrated for symptomatic improvement...Current evidence supports long-term treatment with novel corticosteroid formulations, challenging the established treatment paradigm of EoE. BOT appears to be the most effective steroid therapy, although head-to-head comparative trials between STCs are needed.
- |||||||||| Jorveza (budesonide orodispersible tablets) / Dr Falk
Review, Journal: Treatment of eosinophlic esophagitis with swallowed topical corticosteroids. (Pubmed Central) - May 15, 2021 Whereas it was shown that disease remission induction of EoE by STCs is highly effective, there is still a lack of data regarding long-term and maintenance therapy. However, current studies on STC maintenance therapy add some movement into the game.
- |||||||||| budesonide / Generic mfg., Budenofalk (budesonide effervescent tablet) / Dr Falk
Journal: EMERGING THERAPIES FOR EOSINOPHILIC ESOPHAGITIS. (Pubmed Central) - Jul 29, 2020 Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article, we will discuss recent advances in EoE treatment with regards to swallowed topical steroids, biological agents, dietary approaches and novel molecular targets.
- |||||||||| budesonide / Generic mfg., Budenofalk (budesonide effervescent tablet) / Dr Falk
Review, Journal: Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. (Pubmed Central) - Jun 23, 2020 The new orodispersible budesonide tablet with effervescent properties is the first approved esophageal-targeted formulation specifically developed for the treatment of EoE, which has become available in many European countries. This article gives an overview of the evolution of topical corticosteroids in EoE and provides an update on recent data from large-scale multicenter trials exploring the efficacy and safety of the orodispersible budesonide tablet with effervescent properties in adult EoE patients.
- |||||||||| Jorveza (budesonide orodispersible tablets) / Dr Falk
Enrollment closed, Trial completion date: EOS-2: Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis (clinicaltrials.gov) - Feb 12, 2019 P3, N=204, Active, not recruiting, This article gives an overview of the evolution of topical corticosteroids in EoE and provides an update on recent data from large-scale multicenter trials exploring the efficacy and safety of the orodispersible budesonide tablet with effervescent properties in adult EoE patients. Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Dec 2020
- |||||||||| Jorveza (budesonide orodispersible tablets) / Dr Falk
Enrollment open, Trial initiation date, Trial primary completion date: EOS-1: Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis (clinicaltrials.gov) - Jan 21, 2016 P3, N=90, Recruiting, Initiation date: Aug 2015 --> Feb 2016 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Nov 2015 | Trial primary completion date: Mar 2017 --> Sep 2017
|